Mineralys Therapeutics, Common Stock Analysis

Mineralys Stock Analysis Notes

About 87.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.66. Mineralys Therapeutics, had not issued any dividends in recent years. To find out more about Mineralys Therapeutics, Common contact Jon Congleton at 888 378 6240 or learn more at https://mineralystx.com.

Mineralys Therapeutics, Investment Alerts

Mineralys Therapeutics, Upcoming and Recent Events

Mineralys Largest EPS Surprises

View All Earnings Estimates

Mineralys Therapeutics, Environmental, Social, and Governance (ESG) Scores

Mineralys Therapeutics, Thematic Classifications

Mineralys Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.05 B.

Mineralys Profitablity

Management Efficiency

Mineralys Therapeutics, has return on total asset (ROA) of (0.5256) % which means that it has lost $0.5256 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8224) %, meaning that it created substantial loss on money invested by shareholders. Mineralys Therapeutics,'s management efficiency ratios could be used to measure how well Mineralys Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.91 in 2025. Return On Capital Employed is likely to drop to -1.06 in 2025. Total Assets is likely to drop to about 128.6 M in 2025. Net Tangible Assets is likely to gain to about (44.7 M) in 2025

Technical Drivers

As of the 27th of March, Mineralys Therapeutics, secures the Risk Adjusted Performance of 0.0943, downside deviation of 4.79, and Mean Deviation of 4.34. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mineralys Therapeutics,, as well as the relationship between them. Please verify Mineralys Therapeutics, standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Mineralys Therapeutics, Common is priced some-what accurately, providing market reflects its recent price of 15.0 per share. Given that Mineralys Therapeutics, has jensen alpha of 0.7045, we recommend you to check Mineralys Therapeutics,'s last-minute market performance to make sure the company can sustain itself at a future point.

Mineralys Therapeutics, Price Movement Analysis

Mineralys Therapeutics, Insider Trading Activities

Mineralys Therapeutics, Outstanding Bonds

Mineralys Therapeutics, Predictive Daily Indicators

Mineralys Therapeutics, Corporate Filings

Mineralys Therapeutics, Forecast Models

Mineralys Therapeutics,'s time-series forecasting models are one of many Mineralys Therapeutics,'s stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Mineralys Therapeutics,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Mineralys Therapeutics, prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Mineralys shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Mineralys Therapeutics,. By using and applying Mineralys Stock analysis, traders can create a robust methodology for identifying Mineralys entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Mineralys analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Mineralys analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Mineralys Therapeutics, Common stock analysis indicators help investors evaluate how Mineralys Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Mineralys Therapeutics, shares will generate the highest return on investment. By understating and applying Mineralys Therapeutics, stock analysis, traders can identify Mineralys Therapeutics, position entry and exit signals to maximize returns.

When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.